A Phase 3 Randomized, Open-Label, Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies versus Lenalidomide Plus Rituximab in Patients with Relapsed/Refractory Follicular or Marginal Zone Lymphoma

Project: Research

Project Details

Project Description

NMA HREC Reference Number: HREC/90639/MonH-2022-343398(v2)
NMA SSA Reference Number: A/90639/MonH-2023-357125(v1)
Monash Health Local Reference: RES-22-0000-668X (formerly RES-22-0000-668A)
StatusActive
Effective start/end date23/03/23 → 22/03/28